In comparison with low expression of CD68, shorter OS and PFS could be found in DLBCL patients with high expression of CD68 (median OS: 19 vs 41 months, P<0.001; median PFS: 11 vs 27 months, P<0.001). This evidence concerns the gene CD68 and diffuse large B-cell lymphoma.